האיחוד האירופי - דנית - EMA (European Medicines Agency)

pfizer europe ma eeig - crizotinib - carcinom, ikke-småcellet lunge - antineoplastiske midler - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.

האיחוד האירופי - דנית - EMA (European Medicines Agency)

gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.

האיחוד האירופי - דנית - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulin glargin - diabetes mellitus - narkotika anvendt i diabetes - behandling af diabetes mellitus hos voksne, unge og børn fra 6 år.

האיחוד האירופי - דנית - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - pioglitazon, glimepirid - diabetes mellitus, type 2 - narkotika anvendt i diabetes - tandemact er indiceret til behandling af patienter med type-2 diabetes mellitus, som vis intolerance over for metformin eller til hvem metformin er kontraindiceret, og der er allerede behandlet med en kombination af pioglitazon og glimepirid.

האיחוד האירופי - דנית - EMA (European Medicines Agency)

esteve pharmaceuticals gmbh - ziconotid - injections, spinal; pain - analgetika - ziconotid er indiceret til behandling af alvorlig kronisk smerte hos patienter, som har brug for intratekal (it) analgesi.

האיחוד האירופי - דנית - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulin human - diabetes mellitus - narkotika anvendt i diabetes - diabetes mellitus hvor behandling med insulin er påkrævet. insulin menneskelige winthrop hurtig er også velegnet til behandling af hyperglykæmiske koma og ketoacidose, samt til at opnå før, intra- og postoperativ stabilisering i patienter med diabetes mellitus.

האיחוד האירופי - דנית - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulin human - diabetes mellitus - narkotika anvendt i diabetes - diabetes mellitus hvor behandling med insulin er påkrævet. insuman rapid er også egnet til behandling af hyperglykæmisk koma og ketoacidose samt for at opnå præ-, intra- og postoperativ stabilisering hos patienter med diabetes mellitus.

האיחוד האירופי - דנית - EMA (European Medicines Agency)

indivior europe limited - buprenorphin, naloxon - opioid-relaterede lidelser - andre narkotika stoffer - substitutionsbehandling for opioidmisbrug, inden for rammerne af medicinsk, social og psykologisk behandling. intentionen med naloxon-komponenten er at afskrække intravenøs misbrug. behandlingen er beregnet til brug hos voksne og unge over 15 år, som har accepteret at blive behandlet for afhængighed.

האיחוד האירופי - דנית - EMA (European Medicines Agency)

sanofi winthrop industrie - insulin glargine, lixisenatide - diabetes mellitus, type 2 - narkotika anvendt i diabetes - suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sglt-2 inhibitors.

האיחוד האירופי - דנית - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiske midler - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.